These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 20085555)

  • 1. The effect of sertindole on QTD and TPTE.
    Nielsen J; Andersen MP; Graff C; Kanters JK; Hardahl T; Dybbro J; Struijk JJ; Meyer JM; Toft E
    Acta Psychiatr Scand; 2010 May; 121(5):385-8. PubMed ID: 20085555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sertindole causes distinct electrocardiographic T-wave morphology changes.
    Nielsen J; Graff C; Hardahl T; Andersen MP; Kristoffersen J; Struijk JJ; Toft E; Meyer JM
    Eur Neuropsychopharmacol; 2009 Oct; 19(10):702-7. PubMed ID: 19457646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac effects of sertindole and quetiapine: analysis of ECGs from a randomized double-blind study in patients with schizophrenia.
    Nielsen J; Matz J; Mittoux A; Polcwiartek C; Struijk JJ; Toft E; Kanters JK; Graff C
    Eur Neuropsychopharmacol; 2015 Mar; 25(3):303-11. PubMed ID: 25583364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of sertindole on QTc interval in patients with schizophrenia.
    Atmaca M; Yavuzkir M; Mermi O; Topuz M; Kanmaz E; Tezcan E
    Neurosci Lett; 2008 Sep; 442(1):1-3. PubMed ID: 18639380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug safety and efficacy evaluation of sertindole for schizophrenia.
    Karamatskos E; Lambert M; Mulert C; Naber D
    Expert Opin Drug Saf; 2012 Nov; 11(6):1047-62. PubMed ID: 22992213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].
    Ames D; Camm J; Cook P; Falkai P; Gury C; Hurley R; Johnson G; Piepho R; Vieweg V;
    Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation.
    Eckardt L; Breithardt G; Haverkamp W
    J Pharmacol Exp Ther; 2002 Jan; 300(1):64-71. PubMed ID: 11752098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antipsychotic drugs and cardiovascular safety: current studies of prolonged QT interval and risk of ventricular arrhythmia].
    Gury C; Canceil O; Iaria P
    Encephale; 2000; 26(6):62-72. PubMed ID: 11217540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. QTc interval prolongation and antipsychotic drug treatments: focus on sertindole.
    Lindström E; Farde L; Eberhard J; Haverkamp W
    Int J Neuropsychopharmacol; 2005 Dec; 8(4):615-29. PubMed ID: 15963244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation?
    Mayet S; Gossop M; Lintzeris N; Markides V; Strang J
    Drug Alcohol Rev; 2011 Jul; 30(4):388-96. PubMed ID: 21355918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety of atypical antipsychotics: does QTc provide all the answers?
    Nielsen J
    Expert Opin Drug Saf; 2011 May; 10(3):341-4. PubMed ID: 21504386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case series of drug-induced long QT syndrome and Torsade de Pointes.
    Tong KL; Lau YS; Teo WS
    Singapore Med J; 2001 Dec; 42(12):566-70. PubMed ID: 11989578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Literature review and pilot studies of the effect of QT correction formulas on reported beta2-agonist-induced QTc prolongation.
    Milic M; Bao X; Rizos D; Liu F; Ziegler MG
    Clin Ther; 2006 Apr; 28(4):582-90. PubMed ID: 16750469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sulpiride induced torsade de pointes.
    Huang BH; Hsia CP; Chen CY
    Int J Cardiol; 2007 Jun; 118(3):e100-2. PubMed ID: 17408770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sample size, power calculations, and their implications for the cost of thorough studies of drug induced QT interval prolongation.
    Malik M; Hnatkova K; Batchvarov V; Gang Y; Smetana P; Camm AJ
    Pacing Clin Electrophysiol; 2004 Dec; 27(12):1659-69. PubMed ID: 15613131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beat-to-beat variability of QT intervals is increased in patients with drug-induced long-QT syndrome: a case control pilot study.
    Hinterseer M; Thomsen MB; Beckmann BM; Pfeufer A; Schimpf R; Wichmann HE; Steinbeck G; Vos MA; Kaab S
    Eur Heart J; 2008 Jan; 29(2):185-90. PubMed ID: 18156612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, cardiac safety and tolerability of sertindole: a drug surveillance.
    Pezawas L; Quiner S; Moertl D; Tauscher J; Barnas C; Küfferle B; Wolf R; Kasper S
    Int Clin Psychopharmacol; 2000 Jul; 15(4):207-14. PubMed ID: 10954060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Sertindole Safety Survey: a retrospective analysis under a named patient use programme in Europe.
    Lançon C; Toumi M; Sapin C; Hansen K
    BMC Psychiatry; 2008 Jul; 8():57. PubMed ID: 18638382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Late potentials and QT dispersion after high-dose chemotherapy in patients with non-Hodgkin lymphoma.
    Kuittinen T; Jantunen E; Vanninen E; Mussalo H; Nousiainen T; Hartikainen J
    Clin Physiol Funct Imaging; 2010 May; 30(3):175-80. PubMed ID: 20132128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Schizophrenia, antipsychotic drugs, and cardiovascular disease.
    Glassman AH
    J Clin Psychiatry; 2005; 66 Suppl 6():5-10. PubMed ID: 16107178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.